γδ T 细胞在抗肿瘤免疫中的机制与应用

γδ T cells represent a distinctive subset of immune cells with considerable promise in cancer immunotherapy. They recognize a broad spectrum of tumor-associated antigens via non-major histocompatibility complex (non-MHC) pathways and exert antitumor effects by inducing apoptosis, directly lysing tumor cells, and modulating other immune components.

This unique antigen-recognition capacity has spurred extensive efforts to harness γδ T cells for innovative immunotherapeutic applications. Consequently, their use in cancer treatment is gaining increasing traction. Researchers have employed genetic engineering and other strategies to enhance γδ T cell anti-tumor efficacy and have begun evaluating their potential in clinical trials.

However, this therapeutic approach faces notable challenges, including interindividual variability in response and risk of adverse effects. Future research should aim to achieve a more comprehensive understanding of the mechanisms of γδ T cells across different tumor types and improve their safety and efficacy in clinical settings.

This review synthesizes recent advances in γδ T cell research, examining their roles in tumor recognition, cytotoxicity, immunoregulation, and anti-tumor immunity. It further evaluates preclinical and clinical evidence to assess the therapeutic potential of γδ T cell-based cancer immunotherapies.

Our immune system includes a wide variety of cells that help defend the body against infections and diseases, including cancer. This article focuses on a special type of immune cell called γδ T cells (pronounced “gamma-delta T cells”), which have unique abilities that make them promising tools for cancer treatment. Unlike other immune cells that need specific markers to recognize harmful cells, γδ T cells can detect signs of stress or damage directly on tumor cells. This means they can respond faster and more broadly to different types of cancer. They also release proteins called cytokines that help coordinate the immune response and can directly kill cancer cells. Researchers are exploring different ways to use γδ T cells to treat cancer. One approach involves collecting these cells from patients or healthy donors, growing them in the lab, and then putting them back into the patient’s body to attack tumors.

Another method involves genetically engineering the cells to make them even better at recognizing and destroying cancer cells. Early studies show these treatments are safe, but scientists are still working on making them more effective. The article also discusses how the environment around a tumor—called the tumor microenvironment—can make it harder for immune cells to work.

Researchers are now designing strategies to help γδ T cells survive and stay active in these difficult conditions. While these therapies are still in the early stages of testing, they offer new hope for improving cancer treatment. With continued research, γδ T cells could become a powerful part of future cancer therapies, especially when used together with other treatments like chemotherapy or immunotherapy.